NO3065764T3 - - Google Patents

Info

Publication number
NO3065764T3
NO3065764T3 NO14795569A NO14795569A NO3065764T3 NO 3065764 T3 NO3065764 T3 NO 3065764T3 NO 14795569 A NO14795569 A NO 14795569A NO 14795569 A NO14795569 A NO 14795569A NO 3065764 T3 NO3065764 T3 NO 3065764T3
Authority
NO
Norway
Application number
NO14795569A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3065764T3 publication Critical patent/NO3065764T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57572Gastrin releasing peptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO14795569A 2013-11-06 2014-10-23 NO3065764T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20130191807 EP2870972A1 (en) 2013-11-06 2013-11-06 Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
PCT/EP2014/072697 WO2015067473A1 (en) 2013-11-06 2014-10-23 Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment
EP14795569.4A EP3065764B3 (en) 2013-11-06 2014-10-23 Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment

Publications (1)

Publication Number Publication Date
NO3065764T3 true NO3065764T3 (pl) 2018-07-21

Family

ID=49518847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14795569A NO3065764T3 (pl) 2013-11-06 2014-10-23

Country Status (19)

Country Link
US (3) US10130724B2 (pl)
EP (2) EP2870972A1 (pl)
JP (3) JP2017501116A (pl)
KR (2) KR102039930B1 (pl)
CN (1) CN105705159B (pl)
CY (1) CY1120117T1 (pl)
DK (1) DK3065764T6 (pl)
ES (1) ES2670582T7 (pl)
HR (1) HRP20180631T1 (pl)
HU (1) HUE036943T2 (pl)
LT (1) LT3065764T (pl)
NO (1) NO3065764T3 (pl)
PL (1) PL3065764T6 (pl)
PT (1) PT3065764T (pl)
RS (1) RS57137B1 (pl)
SI (1) SI3065764T1 (pl)
SM (1) SMT201800240T1 (pl)
TR (1) TR201802723T4 (pl)
WO (1) WO2015067473A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870972A1 (en) 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
CN110177565A (zh) * 2016-09-09 2019-08-27 目标实验室有限责任公司 胆囊收缩素2受体靶向近红外成像及其用途
EP3412303A1 (en) * 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
EP3459559A1 (en) * 2017-09-21 2019-03-27 Paul Scherrer Institut Minigastrin derivates, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment
JP6999809B2 (ja) 2018-06-22 2022-02-04 株式会社Junten Bio 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法
WO2019245039A1 (ja) 2018-06-22 2019-12-26 株式会社Junten Bio 感染性免疫寛容を惹起するための組成物
KR20250096878A (ko) 2018-06-22 2025-06-27 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또는 유도된 림프구를 이용하는 세포 치료제 및 치료법
EP3868394A1 (en) * 2020-02-20 2021-08-25 Paul Scherrer Institut Mono- and multi-triazolominigastrins for targeting of cck2r-positive neoplasms
WO2021186060A1 (en) 2020-03-20 2021-09-23 Debiopharm International S.A. Radiolabeled gastrin analogue for use in a method of treating and/or imaging cckb receptor positive diseases, in particular pulmonary and extrapulmonary small-cell carcinoma
EP4188455A1 (en) * 2020-07-31 2023-06-07 Paul Scherrer Institut Composition comprising a rapalog and a radiolabelled gastrin analogue, in particular for use in the treatment and/or diagnosis of cckb receptor positive cancer or tumors
KR20230028515A (ko) * 2020-07-31 2023-02-28 폴 슈레 앙스띠뛰 알파 방사성표지된 가스트린 유사체 및 cckb 수용체 양성 질환의 치료 방법에서의 그의 용도
US20230270893A1 (en) 2020-07-31 2023-08-31 Debiopharm International S.A. Gallium-labeled gastrin analogue and use in a method of imaging cckb-receptor-positive tumors or cancers
WO2022167057A1 (en) 2021-02-02 2022-08-11 Medizinische Universität Innsbruck Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
WO2023051897A1 (en) 2021-09-28 2023-04-06 Debiopharm International S.A. Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer
CN113929737B (zh) * 2021-10-20 2024-07-23 中国科学院香港创新研究院再生医学与健康创新中心 一种多肽及其作为cck受体激动剂/拮抗剂的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
EP2870972A1 (en) * 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment

Also Published As

Publication number Publication date
US10953114B2 (en) 2021-03-23
US10130724B2 (en) 2018-11-20
WO2015067473A1 (en) 2015-05-14
JP2017501116A (ja) 2017-01-12
LT3065764T (lt) 2018-05-10
RS57137B1 (sr) 2018-07-31
US20190240360A1 (en) 2019-08-08
JP2019218364A (ja) 2019-12-26
PL3065764T6 (pl) 2024-01-15
ES2670582T7 (es) 2024-05-31
EP3065764A1 (en) 2016-09-14
TR201802723T4 (tr) 2018-03-21
US20160256580A1 (en) 2016-09-08
CY1120117T1 (el) 2018-12-12
HRP20180631T1 (hr) 2018-06-01
EP2870972A1 (en) 2015-05-13
KR20160070160A (ko) 2016-06-17
EP3065764B1 (en) 2018-02-21
US11623014B2 (en) 2023-04-11
HUE036943T2 (hu) 2018-08-28
JP6763069B2 (ja) 2020-09-30
KR20180094125A (ko) 2018-08-22
PT3065764T (pt) 2018-03-28
KR102039930B1 (ko) 2019-11-05
SMT201800240T1 (it) 2018-07-17
US20210145990A1 (en) 2021-05-20
JP2018118996A (ja) 2018-08-02
SI3065764T1 (en) 2018-05-31
DK3065764T6 (da) 2023-11-06
PL3065764T3 (pl) 2018-07-31
ES2670582T3 (es) 2018-05-31
CN105705159A (zh) 2016-06-22
DK3065764T3 (en) 2018-03-12
JP6568618B2 (ja) 2019-08-28
CN105705159B (zh) 2021-02-12
EP3065764B3 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
AP2016009275A0 (pl)
BR112015007533A2 (pl)
BR102016010778A2 (pl)
BR112014017733A2 (pl)
BR112014018502A2 (pl)
BR112014017739A2 (pl)
BR112014019326A2 (pl)
BR112014018516A2 (pl)
BR112014018480A2 (pl)
BR112014017855A2 (pl)
BR112014020341A2 (pl)
BR112014017765A2 (pl)
BR112014017669A2 (pl)
BR112014021878A2 (pl)
BR112014019204A2 (pl)
BR112014018468A2 (pl)
BR112014017901A2 (pl)
BR112014018207A2 (pl)
NO3065764T3 (pl)
BR112015015948A2 (pl)
BR112014017722A2 (pl)
BR112014017794A2 (pl)
BR112014017653A2 (pl)
BR112014018578A2 (pl)
BR112014018483A2 (pl)